Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure

Phase 1/2 Completed 45 enrolled Horng Chen American Heart Association · collab National Center for Research Resources (NCRR) · collab National Heart, Lung, and Blood Institute (NHLBI) · collab Scios, Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effects of subcutaneous injection of Human BNP (nesiritide), a hormone produced by the heart, on the pumping ability of the heart, kidney function, and hormonal function in persons with heart failure.

Timeline

Start: 2000-01
Primary completion: 2008-07
Completion: 2010-06

Publications

Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr. Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol. 2012 Dec 4;60(22):2305-12. doi: 10.1016/j.jacc.2012.07.056. Epub 2012 Nov 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nesiritide	Protein / enzyme biologic	10 ug/kg	Subcutaneous

Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure

Summary

Timeline

Publications

Drugs

Indications